Brief: Neovacs announces license agreement for Ifnalpha Kinoid for treatment of lupus in Turkey
05/07/2017 06:00
July 5 (Reuters) - NEOVACS SA ALNEV.PA
* REG-NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNALPHA
KINOID FOR TREATMENT OF LUPUS IN TURKEY
* REG-NEOVACS ANNOUNCES LICENSE AGREEMENT FOR IFNALPHA
KINOID FOR TREATMENT OF LUPUS IN TURKEY
* UNDER TERMS OF AGREEMENT, NEOVACS WILL RECEIVE A TOTAL OF
EUR 6 MILLION
* WILL RECEIVE DOUBLE DIGIT ROYALTIES ON NET SALES OF
IFNALPHA KINOID IN TURKEY
Source text for Eikon: ID:nGNE9MbSF
Further company coverage: ALNEV.PA
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Neovacs SA
See all newsBrief: Neovacs And FOCH Hospital Commit To Partnership On Research In Pneumology And Allergology
Brief: Neovacs Presented Latest Results On Its Vaccine Candidates Targeting Allergies
Brief: Neovacs H1 Gross Cash Position Down At EUR 6.2 Mln
Brief: Neovacs: Signature Of Trust Agreement For Equitization Of Bonds Redeemable In Shares With Share Warrants
Brief: Neovacs Launches A Public Offering Of Bonds Redeemable In Shares With Stock Warrants